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ABSTRACT: During the process of aseptic loosening of prostheses, particulate wear debris induces a continuous inflammatory-like
response resulting in the formation of a layer of fibrous peri-prosthetic tissue at the bone-prosthesis interface. The current treatment for
loosening is revision surgery which is associated with a high-morbidity rate, especially in old patients. Therefore, less invasive
alternatives are necessary. One approach could be to re-establish osseointegration of the prosthesis by inducing osteoblast differentiation
in the peri-prosthetic tissue. Therefore, the aim of this study was to investigate the capacity of peri-prosthetic tissue cells to differentiate
into the osteoblast lineage. Cells isolated from peri-prosthetic tissue samples (n¼22)obtained during revision surgerieswere cultured
under normal and several osteogenic culture conditions. Osteogenic differentiation was assessed by measurement of Alkaline Phosphatse
(ALP), mineralization of the matrix and expression of several osteogenic genes. Cells cultured in osteogenic medium showed a significant
increase in ALP staining (p¼0.024), mineralization of the matrix (p< 0.001) and ALP gene expression (p¼ 0.014) compared to normal
culture medium. Addition of bone morphogenetic proteins (BMPs), a specific GSK3b inhibitor (GIN) or a combination of BMP and GIN to
osteogenic medium could not increase ALP staining, mineralization, and ALP gene expression. In one donor, addition of GIN was
required to induce mineralization of the matrix. Overall, we observed a high-inter-donor variability in response to osteogenic stimuli. In
conclusion, peri-prosthetic tissue cells, cultured under osteogenic conditions, can produce alkaline phosphatase and mineralized matrix,
and therefore show characteristics of differentiation into the osteoblastic lineage.  2016 The Authors. Journal of Orthopaedic Research
published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res 35:1732–1742, 2017.
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Aseptic loosening is the most common long-term cause
of failure in total joint arthroplasty.1 The process of
loosening is thought to be a complex interplay between
mechanical as well as biological factors. Particulate
wear debris, continuously generated by articulating
motion at the bearing surfaces, has been implicated as
one of the primary causes initiating peri-prosthetic bone
loss.2 Subsequently, a fibrous-like peri-prosthetic tissue
layer with poor mechanical properties is formed, trigger-
ing bone resorption and prosthesis displacement.3
The current treatment for aseptically loosened pros-
theses is invasive revision surgery, which consists of
removal of the old prosthesis together with the peri-
prosthetic tissue, and insertion of a new prosthesis.
Sometimes, in addition, bone augmentation has to be
done with allograft bone, depending on the severity of
bone loss. This procedure is highly demanding for the
patient and is associated with blood loss, complications,
and morbidity, especially in elderly patients with a poor
general health condition.4–6 Furthermore, revision pros-
theses display poorer clinical and functional performance
than that of the primary prosthesis.7–9 Therefore, less
demanding therapies alternative to extensive revision
surgery but with adequate functional performance are
necessary. Currently, several minimally invasive techni-
ques are being investigated to remove the peri-prosthetic
tissue and stabilize the loosened prosthesis by subse-
quent bone cement injection.10,11
Another approach would be to promote bone forma-
tion in the peri-prosthetic tissue in order to compen-
sate peri-prosthetic bone loss and subsequently
stabilize the loosened prosthesis. This could be accom-
plished in a minimally invasive way by percutaneous,
local introduction of osteogenic factors at the
peri-prosthetic space, which will drive osteogenic dif-
ferentiation of peri-prosthetic tissue cells.
However, little is known about the role of
peri-prosthetic tissue cells in bone formation. Most effort
so far has been concentrated on understanding the role
of these cells in bone resorption around the implant. The
few studies investigating their role in bone formation
show that peri-prosthetic tissue cells produce factors
that suppress osteoblast function and induce production
of inflammatory cytokines.12,13 Moreover, wear particles
and metal ions can directly affect osteoblasts by reducing
type one collagen production14,15 and decreasing alkaline
phosphatase activity as well as calcium deposition.16 In
addition, wear particles have been shown to decrease
osteoblast proliferation,15,17 change the phenotype of
mature osteoblasts,18 and stimulate osteoblasts to se-
crete inflammatory cytokines.14–16,19 Remarkably, one
study revealed that cells from the peri-prosthetic tissue
produce several osteoblastic proteins themselves.20 In
agreement, histological assessment of peri-prosthetic
tissue demonstrated that this tissue exhibits osteogenic
characteristics as shown by the presence of intramem-
branous formation of osteoid,21,22 an increased mineral
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apposition rate and bone formation rate with active
osteoblast lining, and production of immature bone
matrices with poor bone quality.22 Furthermore, an
increased expression of several bone morphogenetic
proteins (BMPs) in several cell types of the peri-
prosthetic tissue was found.23 As BMPs are regulators
and potent inducers of osteoblast differentiation,24 the
local increase of BMP synthesis in peri-prosthetic tissue
could be an attempt to regenerate or maintain implant
fixation. However, to our knowledge, nothing is known
about the capability of peri-prosthetic tissue cells to (re)
generate bone themselves. Therefore, the aim of this
study is to investigate whether cells within the peri-




Peri-prosthetic tissue samples harvested from aseptically
loosened femoral stems or acetabular components of 22
patients were obtained during revision surgery of total hip
replacements. The peri-prosthetic tissue was collected as
“waste” material and as such should not be traceable to
specific patients according to Dutch Medical Ethics laws and
legislation. Therefore, only limited donor characteristics are
available (see Table 1). Collected samples were kept in sterile
NaCl 0.9% at 4˚C, for a maximum of 24h, until they were
processed. This study was approved by the Medical Ethics
Committee of Leiden University Medical Center (C12-107).
Cell Culture
Collected tissue samples were minced and incubated at
37˚C for 2h in a-MEM (Gibco, Carlsbad, CA) with collagenase
I A (2mg/ml; Sigma–Aldrich, St Louis, MO). The cell suspen-
sion was then centrifuged and washed twice in a-MEM
supplemented with 10% Fetal Calf Serum (FCS; Greiner Bio
One, Kremsm€unster, Austria). Cells were cultured in petri-
dishes in a-MEM supplemented with 10% FCS, 1% Glutamax
(Gibco), 3% penicillin and streptomycin (Gibco), and 25mg/ml
Amphotericin B (Gibco) for 72h. Thereafter, cells were
cultured in the same medium but without Amphotericin B.
When cultures reached 90% confluence, the cells were trans-
ferred to 75 cm2 flasks. For the experiments cells from passage
1 or 2 were used.
The human osteosarcoma cell line SaOS-2 (ATCC,
Manassas, VA) and the human dermal fibroblast cell line
(HDF-a; ScienCell, Carlsbad, CA) were cultured in DMEM
(Gibco) supplemented with 10% FCS and 1% penicillin and
streptomycin (Gibco). These cell lines were used as positive
and negative controls in the experiments, respectively.
Osteogenic Differentiation Experiments
Peri-prosthetic tissue cells were seeded at a density of 8,650cells/
cm2. To induce osteoblast differentiation, normal culture
medium (NM, as described above) was supplemented with
freshly added ascorbic acid (50mg/ml; Merck Inc., Kenilworth,
NJ), b-glycerophosphate (5mM; Sigma–Aldrich), and dexameth-
asone (0.1mM; Sigma–Aldrich) with or without recombinant
human BMP-2, BMP- 6 (50ng/ml; R&D Systems, Minneapolis,
MN) or a specific GSK3b inhibitor (GIN; 10nM; kindly provided
by Dr. Rawadi, Prostrakan, France; Engler et al.25) Cell cultures
were subjected randomly to either BMP-2 or BMP-6. The culture
medium was replaced every 3 to 4 days.
Alkaline Phosphatase Activity
Alkaline Phosphatase (ALP) activity was assessed by both
histochemical staining and a colorimetric assay. For ALP
Table 1. Demographic Data From Included Peri-Prosthetic Tissue Samples
Donor Sex Age Fixation Bearing Cup/Stem Years in Situ Visible Presence of Wear Debris
1 F 81 Cemented Metal/PE Cup >5 Yes
2 M 74 Cementless Metal/PE Cup >5 No
3 F 85 Cemented Metal/PE Cup >5 Yes
4 M 59 Cemented Metal/PE Stem >5 Yes
5 M 81 Cemented Metal/PE Cup >5 No
6 F 79 Cemented Metal/PE Stem >5 Yes
7 M 55 Cementless Metal/Metal Cup >5 Yes
8 F 80 Cemented Metal/PE Cup >5 No
9 F 73 Cementless N/A N/A >5 Yes
10 F 75 Cementless Ceramic/PE N/A >5 No
11 F N/A Cemented Metal/PE Cup >5 Yes
12 M 79 Cemented Metal/PE CupþStem >5 No
13 F 80 Cementless Metal/PE Cup >5 No
14 F 86 Cemented Ceramic/PE Cup >5 Yes
15 M 32 Cemented Metal/PE Cup 2–5 Yes
16 F 76 Cementless Ceramic/PE Cup >5 No
17 F 74 Cemented Metal/PE CupþStem >5 No
18 M 69 Cemented Metal/PE N/A >5 Yes
19 M 84 Cemented Metal/PE Stem >5 Yes
20 F 71 Cementless Metal/PE N/A >5 No
21 M 66 Cemented Metal/PE Cup >5 Yes
22 F 80 Cemented Metal/PE Stem 2–5 Yes
F, Female; M, Male; PE, Polyethylene; N/A, Not available.
PERI-PROSTHETIC LOOSENING MEMBRANE CELLS SHOW OSTEOGENIC CAPACITY 1733
JOURNAL OF ORTHOPAEDIC RESEARCH AUGUST 2017
staining, cells were cultured for 18/21 days after which they
were fixed in 3.7% buffered formaldehyde and stained with a
solution containing 0.1mg/ml naphthol ASMX phosphate
(Sigma), 0.5% N, N-dimethylformamide, 2mM MgCl2, and
0.6mg/ml of fast blue BB salt (Sigma) in 0.1mM Tris–HCl
(pH 8.5) for 5min. Thereafter, ALP staining was completely
washed out of the cell layer with a freshly prepared solution
of 50mM NaOH in EtOH. The absorbance was measured at
500nM using a VERSAmax Tunable Microplate Reader
(Molecular Devices, Sunnyvale, CA). Enzymatic ALP activity
was measured after 4, 6, 13, 18, 21, 25, 28, and 32 days of
culture using p-nitrophenyl phosphate (pNPP), as described
by van der Horst et al.26 Briefly, the cells were lysed and
ALP activity was measured kinetically using 6mmol/L pNPP
at 405nm using a VERSAmax Tunable Microplate Reader.
DNA concentration in the cell lysate was measured using the
fluorescent dye bisBenzimide H 33,258 (Hoechst 33,258,
Sigma) and was calibrated against a DNA standard (0.5–
10mg/ml herring sperm DNA). ALP activity was corrected for
the amount of DNA in the culture.
Mineralization
Mineralization of the cultures was assessed using the
fluorescent dye Bonetag (Li-COR Biosciences, Lincoln, NE),
as described previously.27 Briefly, 24h before fixation with
3.7% buffered formaldehyde, 2 nM Bonetag 800 was added to
the culture medium. The fixed cells were scanned with the
Odyssey Infrared Imaging System (Li-COR) at a resolution
of 42mm, intensity 6.5 and medium quality. Integrated
intensity (counts/mm2) of each well was calculated by the
Odyssey software.
Quantitative RT-PCR
Total RNA was isolated from cells using RNA-Bee (Tel-Test
Inc., Friendswood, TX). cDNA was synthesized using M-
MLV reverse transcriptase (Promega, Fitchburg WI)
according to the manufacturer’s instructions. Quantitative
RT-PCR was performed using the Quantitect SYBRgreen
PCR kit (Qiagen, Venlo, The Netherlands) with an iQ5
PCR cycler (BioRad, Hercules, CA). For used primer sets,
all spanning at least one intron, see Table 2. Data were
normalized relative to GAPDH expression. Levels of gene
expression in differentiation experiments were expressed as
fold-change relative to expression in SaOS-2 and HDFA
cells using the 2DDCt method. Basal levels of gene expres-
sion at beginning of experiments were expressed as fold-
change relative to expression in positive controls (e.g.,
SaOS-2 cells, HDFA cells, human endothelial cells, and
human monocytes).
Statistical Analysis
Statistical analysis was performed using SPSS (IBM
SPSS Statistics 23). To account for treatment clustering
within donors during osteogenic differentiation, linear
mixed-effects modelling was used to analyze the ALP activity
staining, mineralization, and gene expression data, while
two-way (mineralization) or three-way (ALP cell layer)
ANOVA was used for the outcome measures in the time-
dependent experiments.
Linear regression was performed for testing the relation
between variability levels of ALP activity and/or mineraliza-
tion and patient- and implant characteristics as well as
between levels of mineralization and basal gene expression
levels of “cell-specific” genes. For all tests, a p-value of <0.05
was regarded as statistically significant. Values represent
meanSD, unless stated otherwise.
RESULTS
The effect of osteogenic stimuli on osteogenic differen-
tiation of peri-prosthetic tissue cells was studied in 22
donors after 18–21 days of culture. When cultured in
normal medium (NM), cells displayed ALP activity
(Fig. 1A). Stimulation of cells with osteogenic medium
(OM) significantly increased ALP activity (p¼0.024).
OM supplemented with either BMP-2, GIN and BMP-
2þGIN or, alternatively, supplemented with BMP-6,
and BMP-6þGIN did not significantly increase ALP
activity (Fig. 1B). In all culture conditions, variation
in the level of ALP activity was observed between
donors (Figs. 1A,B). These variations between donors
makes it impossible to assess differences between
BMP-2 and BMP-6. Mineralization of the matrix was
studied using the fluorescent dye Bonetag. When cells
were cultured in NM, little to no fluorescence was
observed, whereas OM induced mineralization in 15
out of 22 donors, although to (very) different extents
(Figs. 2A,B). In 5 out of 15 donors mineralization could
be increased compared to OM when BMP, GIN or
BMPþGIN was added (Supplementary Fig. S1). Inter-
estingly, in donor 3, mineralization could not be
induced by OM alone, but addition of GIN was needed
to induce mineralization. Furthermore, in donor 19,
mineralization could not be induced by OM alone nor
OM with additives (Supplementary Fig. S1). Overall,
addition of BMP, GIN or BMPþGIN could not signifi-
cantly increase mineralization compared to OM
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Figure 1. Alkaline Phosphatase (ALP) staining. (A) Pictures of ALP staining of cell cultures of five representative donors cultured in
NM or stimulated with OM or OM supplemented with either BMP-2 or BMP-6, GIN and BMP-2 or BMP–6þGIN. Bars represent 1mm.
(B) Boxplot showing the mOD after extraction of ALP staining from the cultures of twenty-two donors cultured in NM, OM or OM
supplemented with either BMP-2, GIN or BMP–2þGIN. Values represent meanSD, dots represents 1.5IQR. NM: normal medium;
OM: osteogenic medium; BMP: bone morphogenetic protein; GIN: GSK3b inhibitor; IQR: Inter Quartile Range. p< 0.05 compared to NM.
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Figure 2. Mineralization of the matrix as measured by Bonetag (fluorescent dye). (A) Pictures of Bonetag fluorescent staining of
cultures of five representative donors stimulated with OM or OM supplemented with BMP-2 or BMP-6, GIN and BMP-2 or BMP–
6þGIN. Normal culture medium served as a negative control. Bars represent 5mm. (B) Boxplot showing the Integrated Intensity of
the fluorescence of twenty-two donors stimulated with OM or OM supplemented with either BMP-2, GIN or BMP–2þGIN. Values
represent meanSD, dots represents 1.5IQR. NM: normal medium; OM: osteogenic medium; BMP: bone morphogenetic protein; GIN:
GSK3b inhibitor; IQR: Inter Quartile Range.
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(Fig. 2B). Subsequently, we also investigated the
response to continuous stimulation with BMP-6.
However, there were no significant differences in ALP
activity and mineralization compared to single stimu-
lation at day 4 (data not shown).
The effect of osteogenic stimuli on ALP, Alpha-1
type I collagen (Col1a1) and osteocalcin (OCN) gene
expression was investigated in 19 donors (Fig. 3). OM
and OM supplemented with GIN or BMP-2þGIN
could significantly increase ALP gene expression (resp.
p¼ 0.014, p< 0.001, p¼0.023) compared to NM.
Col1a1 and OCN gene expression were not signifi-
cantly different between culture conditions.
We investigated whether the observed variation in
levels of ALP activity and mineralization between
donors could be explained by patient- and implant
characteristics. Type of fixation (ALP: b¼0.026,
p¼ 0.538; Mineral: b¼174.30, p¼0.875), gender
(ALP: b¼ 0.06, p¼ 0.187; Mineral: b¼ 80.21, p¼ 0.947)
or age (ALP: b¼0.001, p¼ 0.693; Mineral: b¼21.14,
p¼ 0.661) could not explain the found variations in
ALP activity and mineralization.
Next, we tested whether variation observed in
levels of ALP activity and mineralization between
donors could be explained by degree of responsiveness
to osteogenic stimuli. Since ALP activity and minerali-
zation as described above were only measured at a
single time-point (e.g., after 18–21 days of culture),
variations observed in these markers for osteogenic
differentiation could be explained by differences in
response-rate/degree of responsiveness of the cells
from different donors to osteogenic conditions. There-
fore, in five donors, we investigated the response to
osteogenic stimuli over time. Since there was almost
no additional effect of BMPs and/or GIN compared to
OM alone, we decided to investigate only the response
to OM over time. In all donors, at each time-point, we
observed a significant difference (p<0.001) between
culture conditions in ALP activity in the cell layer
(Fig. 4A). For mineralization, all donors showed a
significant different pattern in mineralization when
cultured with OM, with mineralization observed from
day 13, 21, or 28 onwards (Figs. 4B,C). In all cases,
mineralization occurred directly after a decrease in
ALP activity was seen (Fig. 4A).
Furthermore, we investigated whether the observed
variation in osteogenic responsiveness could be
explained by the heterogeneous composition of the cell
population at the start of experiments. Therefore, we
selected several “cell-specific” genes to compare cell
populations between donors. All samples showed the
presence of macrophage, fibroblast, osteoblast, and
endothelial cells, however, a high-inter-donor variabil-
ity in basal gene expression levels of peri-prosthetic
tissue was observed (Fig. 5). No significant associa-
tions were found between levels of Integrated Inten-
sity (mineralization at day 18–21) and gene expression
levels of ALP (b¼474.89, p¼0.91), OCN (b¼72.15,
p¼ 0.115), S100A4 (b¼141.80, p¼0.49), Vimentin
Figure 3. Relative gene expression (2DDCq) of cells stimulated
with osteogenic stimuli. Expression of alkaline phosphatase
(ALP), alpha-1 type I collagen (Col1a1) and osteocalcin (OCN)
was corrected for internal control GAPDH and the geometric
mean of calibrators SaOS-2 and HDFA. Boxplot showing the
meanSD, dots represent 1.5IQR. NM: normal medium; OM:
osteogenic medium; BMP: bone morphogenetic protein; GIN:
GSK3b inhibitor; IQR: Inter Quartile Range. p<0.05, p< 0.01,
p< 0.001.
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(b¼562.25, p¼0.72), Endoglin (b¼13287.76,
p¼ 0.194), Pecam-1 (b¼251941.78, p¼ 0.067) or
CD68 (b¼148.69, p¼0.59).
DISCUSSION
In the current study, we subjected peri-prosthetic
tissue cells to osteogenic stimuli to investigate
whether these cells could differentiate into the
osteoblastic lineage. We observed an increase in
alkaline phosphatase (ALP) activity and a production
of a mineralized matrix upon induction/stimulation
with osteogenic stimuli. Increase of ALP activity
in early stages of osteoblast differentiation is
assumed to reflect the number of progenitor cells
Figure 4. Analysis of differentiation of time course
experiment. (A) ALP activity measured kinetically over
time in cell cultures of five donors cultured in normal
medium (NM) or stimulated with osteogenic medium
(OM). Pictures (B) and Integrated Intensity (C) of
mineralization of the matrix over time of these cultures
measured using the fluorescent dye Bonetag. SaOS-2
cells and HDFA cells served as positive and negative
control, respectively. Values represent meanSD. Bars
represent 5mm.
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Figure 5. Relative gene expression (2^DDCq) of peri-prosthetic tissue cells. Expression of alkaline phosphatase (ALP) and
osteocalcin (OCN) was corrected for internal control GAPDH and relative gene expression in SaOS-2 cells. Expression of S100A4
and vimentin was corrected for internal control GAPDH and relative gene expression in HDFA cells. Expression of Endoglin and
Pecam-1 was corrected for internal control GAPDH and relative gene expression in human endothelial cells. Expression of CD68 was
corrected for internal control GAPDH and relative gene expression in human monocytes.
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committed to osteogenic differentiation in a cell
population.28 In general during differentiation, ALP
first increases and then decreases when mineraliza-
tion is well progressed.28 In agreement, in peri-
prosthetic tissue cultures ALP activity reached a
peak at the onset of mineralization. We also observed
cells stained for ALP activity after 18–21 days of
culture in NM. Furthermore, in one donor, we
noticed an increase in enzymatic ALP activity over
time when cells were cultured in NM. In a study by
Heinemann et al.29 it was found that cells obtained
from granuloma explants from endoprosthetic revi-
sions stained positive for ALP activity, indicating
that in peri-prosthetic tissue a population of cells
could be present that is already committed to the
osteoblastic lineage.
Mineralization of the matrix describes the final
stage of osteoblast/osteogenic differentiation. Instead
of using conventional staining techniques like Alizarin
Red S, we have chosen Bonetag to assess the level of
mineralization in our cultures, since we previously
showed Bonetag to be more sensitive to small changes
in mineralization.27 In the current study, we observed
an increase in mineralization when cells were cultured
with OM. Moreover, since BMPs are known inducers
of osteogenic differentiation,24 and a local increase of
synthesis of several BMPs in the peri-prosthetic tissue
has been reported,23 we also stimulated cells with OM
supplemented with either BMP-2 or BMP-6. Several
BMPs, including BMP-2 and BMP-6, have shown
positive effects on bone formation, fracture healing,
and implant osseointegration in several in vitro and in
vivo animal models.30–33 BMP-2 is even used in
clinical practice for accelerated healing of fractures
and for spinal fusions.30,34 In our recent study using
the murine cell-line KS483, a combination of BMP-4
and GIN (a stimulator of Wnt-signalling) was found to
enhance mineralization and decrease the expression of
Sclerostin (an inhibitor of bone formation) compared to
BMP-4 alone.35 Therefore, we also stimulated cells
with OM supplemented with either GIN or a combina-
tion of GIN and BMP-2 or BMP-6. Our results show
large-inter-donor differences in response to these
stimuli, ranging from no additional effect to necessity
for mineralization to occur. When all data were put
together no significant increase of mineralization
using BMP, GIN or BMPþGIN was observed. There-
fore, we were not able to ascertain a standard formula
or one common pathway which guarantees osteogenic
differentiation in peri-prosthetic tissue cells.
To confirm our hypothesis that there was an inter-
donor degree of responsiveness to osteogenic stimuli,
we performed a time-series experiment using five
representative donors from the first set of experi-
ments. Indeed, we observed an inter-donor degree of
responsiveness as expressed by differences in peak-
height of ALP activity and differences in time till onset
of mineralization. Furthermore, we noticed an intra-
donor difference in degree of mineralization at day 21
between both types of experiments. We speculate that
this results from differences in cell densities or the
fact that the cells were at different passages when
cells were subjected to osteogenic stimuli, and there-
fore, responses were slower or faster.
The RT-PCR results obtained in this study should
be interpreted with care, since we observed variations
between osteogenic and non-osteogenic conditions
regarding the expression of our reference gene (data
not shown). The variation could not be explained by
any type of technical error. Literature, presenting
RT-PCR data of peri-prosthetic tissue cells, shows the
use of several different reference genes like GAPDH,
18S, b-actin, PBGD, HPRT, and RPL32.36–39 We tested
all these genes, widely used as reference genes in peri-
prosthetic tissue samples, but all showed differences
in expression between osteogenic and non-osteogenic
conditions in at least some donors. Variation in the
gene expression levels of reference genes under differ-
ent experimental conditions has already been found in
other studies,40,41 indicating that it is not surprising
we were not able to find the optimal reference gene for
these types of cells (under these types of experimental
conditions). Because of the variation in the expression
level of the reference genes, calculation of cellular
proportions was not possible. Therefore, in future
studies, for example FACS analysis could be used to
obtain data on percentages of different cell types
within each sample.
In this study, we used peri-prosthetic tissue cells
from early passages, since at higher passages the risk
of substantial in vitro growth selection exists.42,43 To
our opinion, a heterogeneous population of cells could
reflect a more in vivo-like response to osteogenic
stimuli. We tried to characterize the cell content of the
tissue by investigating gene expression patterns of
peri-prosthetic tissue cells at the beginning of the
experiments (day 0). Since there is no suitable tissue
to serve as a control for peri-prosthetic tissue, we used
different control cell lines to determine the relative
expression. A high-variation in the gene expression
levels between donors was observed, indicating hetero-
geneous populations of cells, which is in line with
several studies evaluating the cellular content of peri-
prosthetic tissue.43–45 Although we did not find an
association between the responsiveness to osteogenic
stimuli and the cell content, it is not excluded that the
high-inter-donor variability in gene expression levels
might account for the high-inter-donor variability in
response to osteogenic stimuli.
Besides tissue characteristics (such as cell content
of the tissue), implant and/or patients characteristics,
might explain some of the observed variability in the
osteogenic responsiveness between the peri-prosthetic
tissue of the patients. In our study, prosthesis charac-
teristics (i.e., type of fixation) could not explain the
variability in response to osteogenic stimuli. However,
other studies showed that surface characteristics of
implants can influence the inflammatory response to
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implant material and subsequently affect the expres-
sion of bone formation markers (e.g., BMP-2 and
ALP).46,47 Therefore, in future studies, the effect of
different implant materials and surface characteristics
on osteogenic differentiation of peri-prosthetic tissue
cells should be investigated. In addition, potentially
relevant patient- and tissue-related characteristics,
such as type of bone loss (linear vs. erosive) and in
situ location of the tissue should be taken in to
account. Despite our relatively large number of sam-
ples for an in vitro study, the sample size was still too
small to perform proper association studies between
different clinical groups. Therefore, in future studies,
larger sample sizes of peri-prosthetic tissue with more
detailed patient-, implant- and tissue characteristics
might be essential to explain the inter-donor variabil-
ity in response to osteogenic stimuli. As the primary
aim of this study was to determine whether or not
peri-prosthetic cells are capable to differentiate into
the osteoblastic lineage, the experimental set-up was
relatively simple. Further study is needed to deter-
mine the influence of number, size and type of
particles, as well as immune cells, on the osteogenic
capacity of the cells.
To our knowledge, this is the first (in vitro) study
investigating the response of peri-prosthetic tissue
cells to osteogenic stimuli. Altogether, our results
indicate that these cells, cultured under osteogenic
conditions, show characteristics of differentiation into
the osteoblastic lineage (i.e., over time increase of ALP
activity and production of a mineralized matrix),
although a standard formula inducing osteogenic
differentiation was not found in this study.
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